Merck & Co.’s Keytruda Bounces Back In Advanced Gastric Cancer With Pivotal Success
Executive Summary
The US major’s Keytruda has succeeded in a first-line advanced HER2-negative gastric cancer trial, which could help expand its label to a larger population and marks a positive reverse to past troubles in the indication.